Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss treatment approaches in fourth- and later-line multiple myeloma.
Back
Navigating Ongoing CAR T-Cell Therapy Research in Multiple Myeloma
Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss ongoing research with CAR T-cell therapy in multiple myeloma and key data to emerge with this class of agents from the 2025 ASH Annual Meeting.
Navigating Ongoing CAR T-Cell Therapy Research in Multiple Myeloma
Episodes
All
All
Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, detail the drive beyond additional CAR T-cell therapy research in multiple myeloma.
Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, explain the role of bridging therapy alongside CAR T-cell therapy in multiple myeloma.
Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss the investigational CAR T-cell therapy anito-cel in multiple myeloma.
Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss findings from the iMMagine-1 of anito-cel in relapsed/refractory multiple myeloma.
Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss potential targets for novel CAR T-cell therapies in multiple myeloma.
Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, detail key CAR T-cell therapy data in multiple myeloma from ASH 2025.
Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss questions ongoing research with CAR T-cell therapy in multiple myeloma aims to address.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5